While autophagy-related gene variants (e.g., ATG16L1, NOD2, IRGM) confer IBD susceptibility, their variable penetrance and divergent functional impacts across individuals complicate target selection and limit therapeutic generalizability. This evidence concerns the gene ATG16L1 and inflammatory bowel disease.